lepodisiran
Experimental Drug Reduces Deadly Cholesterol by 94% in 2025 Study
A single dose of lepodisiran, an experimental drug, reduced lipoprotein(a) levels by 94% in a 2025 clinical trial, offering hope for millions at risk of heart disease.
A single dose of lepodisiran, an experimental drug, reduced lipoprotein(a) levels by 94% in a 2025 clinical trial, offering hope for millions at risk of heart disease.